Twitxy Saved

Drew Pardoll

@dpardol1

Director of @BloombergKimmel Institute for Cancer Immunotherapy at Johns Hopkins. Opinions are my own.
Joined February 2014
45 Following 1.4K Followers 20 Posts

Latest posts 5

Drew Pardoll @dpardol1
Stay tuned for anti-PD-1 + PARP inhibitor combos in three cancers with only single digit response rates to anti-PD-1 single agent – breast, ovarian and prostate ca. ORR could go to >20% ORR. And NOT only for BRCA-pathway mutant cancers. Could benefit >300K additional pts/yr.